Sanofi SA (NYSE:SNY) shares gapped up prior to trading on Monday . The stock had previously closed at $43.72, but opened at $44.21. Sanofi shares last traded at $43.72, with a volume of 94301 shares changing hands.
Separately, HC Wainwright reissued a “buy” rating on shares of Sanofi in a report on Thursday, February 28th. Eight equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $51.00.
The firm has a market cap of $108.86 billion, a PE ratio of 13.82, a P/E/G ratio of 2.41 and a beta of 0.67. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.22 and a quick ratio of 0.85.
Large investors have recently made changes to their positions in the business. Barrow Hanley Mewhinney & Strauss LLC raised its stake in shares of Sanofi by 10.0% during the 4th quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 22,467,022 shares of the company’s stock worth $975,294,000 after buying an additional 2,039,820 shares during the period. FMR LLC raised its stake in shares of Sanofi by 1.9% during the 1st quarter. FMR LLC now owns 9,233,558 shares of the company’s stock worth $408,862,000 after buying an additional 175,580 shares during the period. Macquarie Group Ltd. raised its stake in shares of Sanofi by 3.1% during the 1st quarter. Macquarie Group Ltd. now owns 3,259,967 shares of the company’s stock worth $144,351,000 after buying an additional 96,849 shares during the period. Lazard Asset Management LLC raised its stake in shares of Sanofi by 47,594.3% during the 1st quarter. Lazard Asset Management LLC now owns 2,384,716 shares of the company’s stock worth $105,595,000 after buying an additional 2,379,716 shares during the period. Finally, Morgan Stanley raised its stake in shares of Sanofi by 10.9% during the 1st quarter. Morgan Stanley now owns 2,344,823 shares of the company’s stock worth $103,829,000 after buying an additional 230,734 shares during the period. 7.04% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “Sanofi (NYSE:SNY) Shares Gap Up to $44.21” was first posted by Markets Daily and is the property of of Markets Daily. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://www.themarketsdaily.com/2019/06/13/sanofi-nysesny-shares-gap-up-to-44-21.html.
About Sanofi (NYSE:SNY)
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
See Also: Price to Earnings Ratio (PE)
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.